AR095098A1 - Derivado de azol benceno con actividad inhibidora de xantina oxidasa - Google Patents
Derivado de azol benceno con actividad inhibidora de xantina oxidasaInfo
- Publication number
- AR095098A1 AR095098A1 ARP140100314A ARP140100314A AR095098A1 AR 095098 A1 AR095098 A1 AR 095098A1 AR P140100314 A ARP140100314 A AR P140100314A AR P140100314 A ARP140100314 A AR P140100314A AR 095098 A1 AR095098 A1 AR 095098A1
- Authority
- AR
- Argentina
- Prior art keywords
- diseases
- optionally substituted
- hydrogen atom
- groups
- group optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Se proporciona un compuesto o una de sus sales aceptables desde el punto de vista farmacéutico o un producto farmacéutico o una composición farmacéutica que contiene el mismo como principio activo, que tiene una excelente actividad inhibidora de xantina oxidasa y es útil como un agente terapéutico o un agente preventivo para enfermedades asociadas con xantina oxidasa tales como gota, hiperuricemia, síndrome de lisis tumoral, cálculos urinarios, hipertensión, dislipidemia, diabetes, enfermedades cardiovasculares tales como ateroesclerosis o insuficiencia cardíaca, enfermedades renales tales como nefropatia diabética, enfermedades respiratorias tales como enfermedades pulmonares obstructivas crónicas, enfermedades de inflamación intestinal o enfermedades autoinmunes. Reivindicación 1: Un compuesto representado por la fórmula (1) o una de sus sales aceptables desde el punto de vista farmacéutico, en donde R¹ representa OR, NRR que puede formar un anillo o SR, en el cual R y R representan en forma independiente un átomo de hidrógeno, un grupo alquilo C₁₋₈ sustituidos en forma opcional con uno o una pluralidad de grupos alcoxi C₁₋₈, átomos de halógeno o grupos hidroxilo, un grupo arilo sustituido en forma opcional con uno o una pluralidad de grupos alquilo C₁₋₈, grupos alcoxi C₁₋₈ o átomos de halógeno, o un grupo heteroarilo sustituido en forma opcional con uno o una pluralidad de grupos alquilo C₁₋₈, grupos alcoxi C₁₋₈ o un átomo de halógeno; R² representa un átomo de hidrógeno o un grupo alquilo C₁₋₈; y X¹, X² y X³; son en forma independiente CR³ o un átomo de nitrógeno, o X¹ es CR³ o un átomo de nitrógeno, y X² y X³ juntos forman un anillo de benceno, en el cual R³ es un átomo de hidrógeno o un grupo alquilo C₁₋₈.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013017167 | 2013-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095098A1 true AR095098A1 (es) | 2015-09-30 |
Family
ID=51262388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100314A AR095098A1 (es) | 2013-01-31 | 2014-01-30 | Derivado de azol benceno con actividad inhibidora de xantina oxidasa |
Country Status (36)
Country | Link |
---|---|
US (1) | US9388174B2 (es) |
EP (1) | EP2952513B1 (es) |
JP (1) | JP5734532B2 (es) |
KR (1) | KR102199258B1 (es) |
CN (1) | CN104968662B (es) |
AR (1) | AR095098A1 (es) |
AU (1) | AU2014213396B2 (es) |
BR (1) | BR112015018033B1 (es) |
CA (1) | CA2897928C (es) |
CL (1) | CL2015002117A1 (es) |
CY (1) | CY1122015T1 (es) |
DK (1) | DK2952513T3 (es) |
ES (1) | ES2744817T3 (es) |
HK (1) | HK1215806A1 (es) |
HR (1) | HRP20191554T1 (es) |
HU (1) | HUE047028T2 (es) |
IL (2) | IL239940B (es) |
LT (1) | LT2952513T (es) |
MA (1) | MA38295B1 (es) |
ME (1) | ME03516B (es) |
MX (1) | MX364483B (es) |
MY (1) | MY181731A (es) |
NZ (1) | NZ709407A (es) |
PE (1) | PE20151329A1 (es) |
PH (2) | PH12015501640A1 (es) |
PL (1) | PL2952513T3 (es) |
PT (1) | PT2952513T (es) |
RS (1) | RS59371B1 (es) |
RU (1) | RU2641891C2 (es) |
SA (1) | SA515360829B1 (es) |
SG (1) | SG11201505993PA (es) |
SI (1) | SI2952513T1 (es) |
TW (1) | TWI606048B (es) |
UA (1) | UA117124C2 (es) |
WO (1) | WO2014119681A1 (es) |
ZA (1) | ZA201505240B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2953931T1 (sl) | 2013-01-31 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Piridon amidi kot modulatorji natrijevih kanalov |
LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
US20170217948A1 (en) | 2014-07-30 | 2017-08-03 | Teijin Pharma Limited | Xanthine oxidase inhibitor |
NZ729045A (en) * | 2014-07-30 | 2022-05-27 | Teijin Pharma Ltd | Crystal of azole benzene derivative |
SG11201700741WA (en) | 2014-07-30 | 2017-02-27 | Teijin Pharma Ltd | Azole benzene derivative and crystalline form thereof |
JP6732004B2 (ja) | 2016-02-19 | 2020-07-29 | 国立大学法人鳥取大学 | 認知症治療薬または予防薬 |
AU2017364804A1 (en) * | 2016-11-28 | 2019-05-02 | Teijin Pharma Limited | Therapeutic drug or prophylactic drug for diabetic nephropathy |
EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
WO2022256622A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645867B2 (en) * | 1990-11-30 | 1994-01-27 | Teijin Pharma Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
ATE270550T1 (de) * | 1995-04-07 | 2004-07-15 | Teijin Ltd | Wirkstoff zum schutz für organ oder gewebe |
NZ307521A (en) * | 1995-04-21 | 1999-04-29 | Meiji Seika Kaisha | 1-(2-(het)ring-)-(het)ring)-4- or 5-benzimidazole derivates as modulators of the gaba receptor complex |
JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
JP5222561B2 (ja) * | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
WO2008126770A1 (ja) * | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
US8227500B2 (en) | 2007-04-11 | 2012-07-24 | Kissei Pharmaceutical Co., Ltd. | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same |
WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
WO2010128163A2 (en) | 2009-05-08 | 2010-11-11 | Pike Pharma Gmbh | Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication |
WO2011101867A2 (en) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Substantially pure salts of febuxostat and processes for preparation thereof |
WO2011139886A2 (en) | 2010-04-29 | 2011-11-10 | Dr. Reddy's Laboratories Ltd. | Preparation of febuxostat |
-
2014
- 2014-01-29 TW TW103103559A patent/TWI606048B/zh active
- 2014-01-30 US US14/442,752 patent/US9388174B2/en active Active
- 2014-01-30 LT LT14746209T patent/LT2952513T/lt unknown
- 2014-01-30 KR KR1020157019782A patent/KR102199258B1/ko active IP Right Grant
- 2014-01-30 MA MA38295A patent/MA38295B1/fr unknown
- 2014-01-30 PL PL14746209T patent/PL2952513T3/pl unknown
- 2014-01-30 ME MEP-2019-262A patent/ME03516B/me unknown
- 2014-01-30 SI SI201431281T patent/SI2952513T1/sl unknown
- 2014-01-30 UA UAA201507650A patent/UA117124C2/uk unknown
- 2014-01-30 MY MYPI2015702266A patent/MY181731A/en unknown
- 2014-01-30 SG SG11201505993PA patent/SG11201505993PA/en unknown
- 2014-01-30 BR BR112015018033-7A patent/BR112015018033B1/pt active IP Right Grant
- 2014-01-30 MX MX2015009655A patent/MX364483B/es active IP Right Grant
- 2014-01-30 PE PE2015001576A patent/PE20151329A1/es active IP Right Grant
- 2014-01-30 AU AU2014213396A patent/AU2014213396B2/en active Active
- 2014-01-30 JP JP2014557920A patent/JP5734532B2/ja active Active
- 2014-01-30 WO PCT/JP2014/052154 patent/WO2014119681A1/ja active Application Filing
- 2014-01-30 CA CA2897928A patent/CA2897928C/en active Active
- 2014-01-30 NZ NZ70940714A patent/NZ709407A/en not_active IP Right Cessation
- 2014-01-30 DK DK14746209.7T patent/DK2952513T3/da active
- 2014-01-30 CN CN201480006601.1A patent/CN104968662B/zh active Active
- 2014-01-30 RU RU2015132105A patent/RU2641891C2/ru active
- 2014-01-30 RS RSP20191244 patent/RS59371B1/sr unknown
- 2014-01-30 EP EP14746209.7A patent/EP2952513B1/en active Active
- 2014-01-30 AR ARP140100314A patent/AR095098A1/es unknown
- 2014-01-30 HU HUE14746209A patent/HUE047028T2/hu unknown
- 2014-01-30 ES ES14746209T patent/ES2744817T3/es active Active
- 2014-01-30 PT PT14746209T patent/PT2952513T/pt unknown
-
2015
- 2015-07-14 IL IL239940A patent/IL239940B/en active IP Right Grant
- 2015-07-21 ZA ZA2015/05240A patent/ZA201505240B/en unknown
- 2015-07-23 PH PH12015501640A patent/PH12015501640A1/en unknown
- 2015-07-29 SA SA515360829A patent/SA515360829B1/ar unknown
- 2015-07-29 CL CL2015002117A patent/CL2015002117A1/es unknown
-
2016
- 2016-04-01 HK HK16103729.4A patent/HK1215806A1/zh unknown
-
2018
- 2018-02-05 PH PH12018500261A patent/PH12018500261B1/en unknown
- 2018-06-05 IL IL259824A patent/IL259824B/en active IP Right Grant
-
2019
- 2019-08-28 HR HRP20191554 patent/HRP20191554T1/hr unknown
- 2019-09-10 CY CY20191100944T patent/CY1122015T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095098A1 (es) | Derivado de azol benceno con actividad inhibidora de xantina oxidasa | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
PH12016500467B1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
PH12016501972A1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
BR112015005243A2 (pt) | métodos para o tratamento de câncer de mama localmente avançado | |
DK2970216T3 (da) | Biarylamidforbindelser som kinaseinhibitorer | |
RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
JP2017505285A5 (es) | ||
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
TR201906325T4 (tr) | Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri. | |
EA201692298A1 (ru) | Производные карбоксамидов | |
EA201890532A1 (ru) | Новые аннелированные бензамиды | |
EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
UY36124A (es) | Derivados de carboxamida | |
AR101364A1 (es) | Derivado de ácido azolcarboxílico | |
BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
TH173740B (th) | สไพโรไซโคลเฮพเทนเป็นสารยับยั้งของ rock | |
TH171902B (th) | สารประกอบเฮเทอโรไซคลิค | |
CU20160170A7 (es) | Derivados de carboxamida | |
TH167246B (th) | สารประกอบไบแอริลเอไมด์ เป็นสารยับยั้งไคเนส | |
TH167738B (th) | 1h-1, 8-แนพไธริดิน-2-โอนในรูปสารประกอบต้านการเพิ่มจำนวน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |